RO4893594, Lucentis 10 mg/ml solution for injection in pre-filled syringe
MR45625
Phase 3 small_molecule active
Quick answer
RO4893594, Lucentis 10 mg/ml solution for injection in pre-filled syringe for Neovascular Age-Related Macular Degeneration (nAMD) is a Phase 3 program (small_molecule) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Roche Registration Limited
- Indication
- Neovascular Age-Related Macular Degeneration (nAMD)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active